Aurion Biotech raises $120m to advance cell therapy programme
Aurion Biotech has raised $120m from biotech and ophthalmology investors to progress its cell therapy programme for corneal edema secondary to endothelial dysfunction.
Aurion Biotech has raised $120m from biotech and ophthalmology investors to progress its cell therapy programme for corneal edema secondary to endothelial dysfunction.
Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.
Bioscience researchers at GE Research have begun an in-depth study to better understand the impact of the Covid-19 virus on the lungs.